These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28444776)

  • 41. Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia.
    Johnson LB; Bradley SF; Kauffman CA
    Mycoses; 1998; 41(7-8):277-80. PubMed ID: 9861831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thiazole derivatives act on virulence factors of Cryptococcus spp.
    de Sá NP; de Barros PP; Junqueira JC; Vaz JA; de Oliveira RB; Rosa CA; Santos DA; Johann S
    Med Mycol; 2019 Jan; 57(1):84-91. PubMed ID: 29471408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergy and antagonism between iron chelators and antifungal drugs in Cryptococcus.
    Lai YW; Campbell LT; Wilkins MR; Pang CN; Chen S; Carter DA
    Int J Antimicrob Agents; 2016 Oct; 48(4):388-94. PubMed ID: 27474467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
    Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role for cell density in antifungal drug resistance in Candida albicans biofilms.
    Perumal P; Mekala S; Chaffin WL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2454-63. PubMed ID: 17502416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of antifungal combinations against Candida albicans biofilms.
    Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
    J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Fungal infectivities of implanted catheters due to Candida sp. Biofilms formation and resistance].
    Seddiki SM; Boucherit-Otmani Z; Boucherit K; Kunkel D
    J Mycol Med; 2015 Jun; 25(2):130-5. PubMed ID: 25957711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First case of continuous ambulatory peritoneal dialysis-related peritonitis caused by Cryptococcus arboriformis.
    Im H; Chae JD; Yoo M; Lee SY; Song EJ; Sung SA; Hwang YH; Shin JH; Cho YU
    Ann Lab Med; 2014 Jul; 34(4):328-31. PubMed ID: 24982841
    [No Abstract]   [Full Text] [Related]  

  • 50. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.
    Serena C; Fernández-Torres B; Pastor FJ; Trilles L; Lazéra Mdos S; Nolard N; Guarro J
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2994-6. PubMed ID: 15980382
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exogenous tyrosol inhibits planktonic cells and biofilms of Candida species and enhances their susceptibility to antifungals.
    Cordeiro Rde A; Teixeira CE; Brilhante RS; Castelo-Branco DS; Alencar LP; de Oliveira JS; Monteiro AJ; Bandeira TJ; Sidrim JJ; Moreira JL; Rocha MF
    FEMS Yeast Res; 2015 Jun; 15(4):fov012. PubMed ID: 25795651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic humicolus cryptococcosis.
    Shinde SM; Vanarse KS; Pandit AN
    Indian Pediatr; 2004 Nov; 41(11):1162-4. PubMed ID: 15591670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity of 3'-hydroxychalcone against Cryptococcus gattii and toxicity, and efficacy in alternative animal models.
    Palanco AC; Lacorte Singulani J; Costa-Orlandi CB; Gullo FP; Strohmayer Lourencetti NM; Gomes PC; Ayusso GM; Dutra LA; Silva Bolzani VD; Regasini LO; Soares Mendes-Giannini MJ; Fusco-Almeida AM
    Future Microbiol; 2017 Oct; 12():1123-1134. PubMed ID: 28876122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro antifungal activity of baicalin against Candida albicans biofilms via apoptotic induction.
    Wang T; Shi G; Shao J; Wu D; Yan Y; Zhang M; Cui Y; Wang C
    Microb Pathog; 2015 Oct; 87():21-9. PubMed ID: 26169236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of fluconazole with silver nanoparticles produced by Fusarium oxysporum improves antifungal effect against planktonic cells and biofilm of drug-resistant Candida albicans.
    Longhi C; Santos JP; Morey AT; Marcato PD; Durán N; Pinge-Filho P; Nakazato G; Yamada-Ogatta SF; Yamauchi LM
    Med Mycol; 2016 May; 54(4):428-32. PubMed ID: 26092103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe.
    Nyazika TK; Herkert PF; Hagen F; Mateveke K; Robertson VJ; Meis JF
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):289-292. PubMed ID: 27608538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression.
    Fontes AC; Bretas Oliveira D; Santos JR; Carneiro HC; Ribeiro NQ; Oliveira LV; Barcellos VA; Paixão TA; Abrahão JS; Resende-Stoianoff MA; Vainstein MH; Santos DA
    Med Mycol; 2017 Feb; 55(2):203-212. PubMed ID: 27486215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Miltefosine inhibits Candida albicans and non-albicans Candida spp. biofilms and impairs the dispersion of infectious cells.
    Vila T; Ishida K; Seabra SH; Rozental S
    Int J Antimicrob Agents; 2016 Nov; 48(5):512-520. PubMed ID: 27667564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.